Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.57 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665175 | 1.00 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL664788 | 1.00 | CACNA2D1 (0.57) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4880767 | 0.92 | CACNA2D1 (0.43) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL665555 | 0.86 | CACNA2D1 (0.59) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL4290966 | 0.85 | TSHR (0.44) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27729213 | 0.85 | TSHR (0.44) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1410027 | 0.85 | CACNA2D1 (0.74) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1419510 | 0.82 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5003775 | 0.82 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1419512 | 0.82 | CACNA2D1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112301017-A | Lipase derived from pseudomonas and application thereof | 江苏美科生物科技有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-113564144-B | Lipase mutant and application thereof | 上海奥博生物医药股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118956817-A | Lipase mutant and application thereof | 上海奥博生物医药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113564144-A | Lipase mutant and application thereof | 上海奥博生物医药技术有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-112301017-A | Lipase derived from pseudomonas and application thereof | 江苏美科生物科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112301017-A | Lipase derived from pseudomonas and application thereof | 江苏美科生物科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019193607-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PREGABALIN | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2019-10-10 | — | — | WO | disclosed |
| US-10023885-B2 | Process for the preparation of pregabalin | HIKAL LIMITED (IN) | 2018-07-17 | — | — | US | disclosed |
| US-20150344919-A1 | PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2015-12-03 | — | — | US | disclosed |
| US-20150344919-A1 | PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2015-12-03 | — | — | US | disclosed |
| WO-2014072785-A2 | A PROCESS FOR THE PREPARATION OF PREGABALIN | HIKAL LIMITED (IN) | 2014-05-15 | — | — | WO | disclosed |
| CN-101448779-A | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | TEVA PHARMA (IL) | 2009-06-03 | — | — | CN | disclosed |
| EP-2019817-A2 | PROCESSES FOR THE PREPARATION OF R-(+)-3-(CARBAMOYL METHYL)-5-METHYLHEXANOIC ACID AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-02-04 | — | — | EP | disclosed |
| US-7462738-B2 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-09 | — | — | US | disclosed |
| US-20070293694-A1 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| WO-2007139933-A2 | PROCESSES FOR THE PREPARATION OF R-(+)-3-(CARBAMOYL METHYL)-5-METHYLHEXANOIC ACID AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293694-A1 | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | RIMKLA, GABRE, GRIK5 | CACNA2D1 245/4885CACNB3 63/4885CACNA1C 43/4885 |
| US-10023885-B2 | Process for the preparation of pregabalin | CHRNA6, CHRNA9, ADH5 | CACNA2D1 164/4885CACNB3 190/4885CACNA1C 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.